William Newsome III and Piet Wigerinck take top Fibrocor jobs

25 October 2023

Fibrocor Therapeutics, a privately-held Canadian developer of therapeutics to treat fibrosis, has named William Newsome III as president and chief executive and Piet Wigerinck as chief scientific advisor.

William P Newsome III was one of the co-founders of Fibrocor when he was with German drug discovery firm Evotec (ETR: EVT) and he has remained closely involved with the company as a non-executive director since 2018.

Dr Wigerinck is a highly experienced drug hunter, having taken four drugs - Prezista (darunavir), Olysio (simeprevir), Jyseleca (filgotinib) and Rekambys (rilpivirine) - to market.

Fibrocor focuses on rare fibrotic indications, including idiopathic pulmonary fibrosis, genetic kidney disorders, chronic allograph nephropathy and primary sclerosing cholangitis, a type of chronic bile duct disease which often leads to liver failure.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK